Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.63 |
| ▸ | NCF1 | P14598 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639261 | 0.85 | PDE10A (0.85) | PDE10A | |
| SCHEMBL5651018 | 0.84 | PDE10A (0.54) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL14367677 | 0.84 | PDE10A (0.54) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4774841 | 0.80 | PDE10A (0.49) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4978026 | 0.78 | PDE10A (0.53) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL4971347 | 0.78 | PDE10A (0.49) | PDE10AEHMT2PDGFRB | |
| SCHEMBL4971821 | 0.77 | PDE10A (0.46) | PDE10ACYP2D6GSK3BNUDT1PDGFRB | |
| SCHEMBL4173257 | 0.77 | PDE10A (0.50) | PDE10ACYP2D6GSK3BPDGFRB | |
| SCHEMBL1638492 | 0.77 | PDE10A (1.00) | PDE10APDGFRB | |
| SCHEMBL1636932 | 0.76 | PDE10A (1.00) | PDE10APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996574-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007103554-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103554-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299067-A1 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | PDE12, PDE10A, PDE4A | PDE10A 2/4885NCF1 2811/4885CYP2D6 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.